The Medicines Evaluation Board (MEB) assesses and monitors the efficacy, risks and quality of human and veterinary medicinal products, and the safety of novel foods for human consumption.
- Strategic objectives
- Medicines Evaluation Board
- Organisation and units
- Regular consultations
- Independence and integrity
The Board consists of a chairperson and at least 9 and at most 17 other members (doctors, pharmacists and scientists). The chairperson and members are appointed by the Minister of Health, Welfare and Sport (VWS). The term of office of the chairperson and the members is 4 years and can be extended twice for 4 years through reappointment. The Board's method of working and responsibilities are laid down in the Medicines Act.
The members of the Board are supported in their work by more than 300 employees of the Medicines Evaluation Board Agency (MEB Agency). As part of the Ministry of Health, Welfare and Sport (VWS) the Agency is responsible for preparing and implementing decisions by the Board and for coordinating pharmacovigilance in the Netherlands.
The Agency also assesses veterinary medicinal products via the Veterinary Medicinal Products Unit and the assessment of novel foods via the Novel Foods Unit. However, the MEB is not responsible for the decision-making and authorisation of veterinary medicinal products and novel foods. The Veterinary Medicinal Products Unit prepares the decision-making of the Veterinary Medicines Board. This Board advises the Minister of Economic Affairs, who is responsible for policy and politics.
In the Netherlands the Ministry of Health, Welfare and Sport (VWS) is the competent authority for assessment of novel foods. The minister asks the Novel Foods Unit of the MEB for a scientific assessment of consumer safety.
MEB Annual Report: a leading player in Europe again in 2016
The Medicines Evaluation Board (MEB) was one of the leading players in Europe in the field of medicine assessment and...
Eric Boersma sworn in as new MEB Member
Mr Prof H. (Eric) Boersma was sworn in as a new member of the Medicines Evaluation Board (MEB) on 1 June 2017.
Anthonius (Ton) de Boer new MEB chairman
Prof. Ton de Boer is to take over as the new chairman of the Medicines Evaluation Board (MEB) as of 1 August 2017. This was...
One step closer to less animal testing
In the future, a part of animal testing for new medicines will no longer be necessary. In most cases, testing on one species of...